{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:11:32Z","timestamp":1781277092079,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.7759\/cureus.75827","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T21:51:29Z","timestamp":1734385889000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Neuromyelitis Optica Spectrum Disorder With Improvement in Urinary Retention After the Administration of Ravulizumab"],"prefix":"10.7759","author":[{"given":"Takuya","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhito","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk DM","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022, 387:631-9. 10.1056\/NEJMra1904655","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk DM","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006, 66:1485-9. 10.1212\/01.wnl.0000216139.44259.74","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1701557","article-title":"Urinary symptoms and bladder dysfunction in patients with neuromyelitis optica spectrum disorders: evaluation with urodynamics and management","volume":"11","author":"Gupta A","year":"2020","unstructured":"Gupta A, Sivaram A, Krishnan R, Khanna M. Urinary symptoms and bladder dysfunction in patients with neuromyelitis optica spectrum disorders: evaluation with urodynamics and management. J Neurosci Rural Pract. 2020, 11:245-9. 10.1055\/s-0040-1701557","journal-title":"J Neurosci Rural Pract"},{"key":"ref4","article-title":"Urinary retention in adults: diagnosis and initial management","volume":"77","author":"Selius BA","year":"2008","unstructured":"Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008, 77:643-50.","journal-title":"Am Fam Physician"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan D","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al.. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018, 13:e0195909. 10.1371\/journal.pone.0195909","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock SJ","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al.. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023, 93:1053-68. 10.1002\/ana.26626","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.2.154","article-title":"Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations","volume":"73","author":"Kalita J","year":"2002","unstructured":"Kalita J, Shah S, Kapoor R, Misra UK. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry. 2002, 73:154-9. 10.1136\/jnnp.73.2.154","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)39381-3","article-title":"Urinary dysfunction in transverse myelitis","volume":"144","author":"Berger Y","year":"1990","unstructured":"Berger Y, Blaivas JG, Oliver L. Urinary dysfunction in transverse myelitis. J Urol. 1990, 144:103-5. 10.1016\/s0022-5347(17)39381-3","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-442270216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk DM","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-15. 10.1016\/S1474-442270216-8","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu Y","year":"2019","unstructured":"Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019, 27:412-8. 10.1016\/j.msard.2018.12.002","journal-title":"Mult Scler Relat Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1011579","article-title":"Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD","volume":"13","author":"Fadda G","year":"2022","unstructured":"Fadda G, Flanagan EP, Cacciaguerra L, Jitprapaikulsan J, Solla P, Zara P, Sechi E. Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol. 2022, 13:1011579. 10.3389\/fneur.2022.1011579","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee JW","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al.. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019, 133:530-9. 10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton S","year":"2022","unstructured":"Chatterton S, Parratt JD, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol. 2022, 13:951423. 10.3389\/fneur.2022.951423","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06971-x","article-title":"Eculizumab for a catastrophic relapse in NMOSD: case report","volume":"45","author":"Gorriz D","year":"2024","unstructured":"Gorriz D, P\u00e9rez-Miralles FC, Quintanilla-Bord\u00e1s C, Alcal\u00e1 C, Frasquet M, Casanova B. Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci. 2024, 45:249-51. 10.1007\/s10072-023-06971-x","journal-title":"Neurol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.863151","article-title":"Chronic cognitive impairment in AQP4+ NMOSD with improvement in cognition on eculizumab: a report of two cases","volume":"13","author":"Saab G","year":"2022","unstructured":"Saab G, Munoz DG, Rotstein DL. Chronic cognitive impairment in AQP4+ NMOSD with improvement in cognition on eculizumab: a report of two cases. Front Neurol. 2022, 13:863151. 10.3389\/fneur.2022.863151","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/324867-a-case-of-neuromyelitis-optica-spectrum-disorder-with-improvement-in-urinary-retention-after-the-administration-of-ravulizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T21:51:31Z","timestamp":1734385891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/324867-a-case-of-neuromyelitis-optica-spectrum-disorder-with-improvement-in-urinary-retention-after-the-administration-of-ravulizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.75827","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}